BioXcel Therapeutics Inc. (BTAI) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

BioXcel Therapeutics Inc. (BTAI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.34

-0.02 (-4.68%)

At close: Jan 15, 2025, 9:46 AM

undefined% (undefined)

Bid	0.34
Market Cap	16.87M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.04
PE Ratio (ttm)	-0.17
Forward PE	n/a
Analyst	Buy

Ask	0.34
Volume	147,728
Avg. Volume (20D)	849,106
Open	0.36
Previous Close	0.36
Day's Range	0.33 - 0.36
52-Week Range	0.30 - 4.17
Beta	undefined

About BTAI

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 8, 2018

Employees 74

Stock Exchange NASDAQ

Ticker Symbol BTAI

Website https://www.bioxceltherapeutics.com

Analyst Forecast

According to 4 analyst ratings, the average rating for BTAI stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 782.35% from the latest price.

Buy 50.00%

Hold 25.00%

Sell 25.00%

Stock Forecasts

Next Earnings Release

BioXcel Therapeutics Inc. is scheduled to release its earnings on Mar 11, 2025, before market opens.
Analysts project revenue of $413.84K, reflecting a 10.06% YoY growth and earnings per share of -0.31, making a -59.21% decrease YoY.

Why Price Moved

1 week ago · Source

-17.78%

BioXcel Therapeutics shares are trading lower afte... Unlock content with Pro Subscription

1 week ago · Source

+38.45%

BioXcel Therapeutics shares are trading higher. Canaccord Genuity maintained a Buy rating on the stock.

News

3 weeks ago · zacks.com

BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade

BioXcel Therapeutics (BTAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · zacks.com

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.72 per share a year ago.

2 months ago · seekingalpha.com

BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript

BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer Richard Steinhart - Chief Financial O...

2 months ago · zacks.com

Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know

BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.